Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC

Patients with RET fusions represent 1-2% of all cases of non-small cell lung cancer (NSCLC), the majority of whom are younger, and are extremely rare in the elderly. As a selective RET inhibitor, pralsetinib has been shown to be efficacious and well-tolerated in patients with RET-fusion NSCLC. Never...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Li, Chen, Pengzhi, Wang, Junfeng, Qin, Xuebing, Liu, Tingting, Gao, Yanhong, Wang, Peng, Zhang, Dong, Fang, Xiangqun, Zhang, Zhijian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773986/
https://www.ncbi.nlm.nih.gov/pubmed/36568233
http://dx.doi.org/10.3389/fonc.2022.1024365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773986/
https://www.ncbi.nlm.nih.gov/pubmed/36568233
http://dx.doi.org/10.3389/fonc.2022.1024365

Ejemplares similares